MX379539B - Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer. - Google Patents

Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.

Info

Publication number
MX379539B
MX379539B MX2019006379A MX2019006379A MX379539B MX 379539 B MX379539 B MX 379539B MX 2019006379 A MX2019006379 A MX 2019006379A MX 2019006379 A MX2019006379 A MX 2019006379A MX 379539 B MX379539 B MX 379539B
Authority
MX
Mexico
Prior art keywords
normal
tumor cells
small molecule
cancer therapy
gene induction
Prior art date
Application number
MX2019006379A
Other languages
English (en)
Spanish (es)
Other versions
MX2019006379A (es
Inventor
Gen Sheng Wu
Joshua E Allen
Wafik S El-Deiry
Original Assignee
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47068061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX379539(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Penn State Res Found filed Critical Penn State Res Found
Publication of MX2019006379A publication Critical patent/MX2019006379A/es
Publication of MX379539B publication Critical patent/MX379539B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019006379A 2011-04-29 2012-04-30 Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer. MX379539B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161480743P 2011-04-29 2011-04-29
PCT/US2012/035831 WO2012149546A2 (en) 2011-04-29 2012-04-30 Small molecule trail gene induction by normal and tumor cells as an anticancer therapy

Publications (2)

Publication Number Publication Date
MX2019006379A MX2019006379A (es) 2019-09-04
MX379539B true MX379539B (es) 2025-03-11

Family

ID=47068061

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019006379A MX379539B (es) 2011-04-29 2012-04-30 Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
MX2013012346A MX365365B (es) 2011-04-29 2012-04-30 Induccion de gen de trail de molécula pequeña en células normales y tumorales como una terapia anticáncer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013012346A MX365365B (es) 2011-04-29 2012-04-30 Induccion de gen de trail de molécula pequeña en células normales y tumorales como una terapia anticáncer.

Country Status (18)

Country Link
US (9) US8673923B2 (enExample)
EP (3) EP4335511B1 (enExample)
JP (7) JP6132833B2 (enExample)
CA (1) CA2832342C (enExample)
CY (1) CY1123010T1 (enExample)
DK (2) DK3679934T3 (enExample)
ES (2) ES2786033T3 (enExample)
FI (1) FI3679934T3 (enExample)
HR (2) HRP20241214T1 (enExample)
HU (2) HUE049207T2 (enExample)
LT (2) LT3679934T (enExample)
MX (2) MX379539B (enExample)
PL (2) PL3679934T3 (enExample)
PT (2) PT2701708T (enExample)
RS (2) RS65813B1 (enExample)
SI (2) SI2701708T1 (enExample)
SM (2) SMT202400421T1 (enExample)
WO (1) WO2012149546A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149546A2 (en) 2011-04-29 2012-11-01 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
US9376437B2 (en) 2013-03-13 2016-06-28 Oncoceutics, Inc 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy
HRP20191181T1 (hr) * 2013-03-13 2019-10-04 Oncoceutics, Inc. 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma
WO2015073072A1 (en) * 2013-11-15 2015-05-21 Oncoceutics, Inc. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one
US9688679B2 (en) 2013-03-13 2017-06-27 Oncoceutics, Inc. 7-benzyl-4-(methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-A]pyrido[3,4-E]pyrimidin-5 (1H)-one, salts thereof and methods of using the same in combination therapy
PL3068401T3 (pl) 2013-11-15 2019-08-30 Oncoceutics, Inc. 7-Benzylo-4-(2-metylobenzylo)-2,4,6,7,8,9-heksahydroimidazo[1,2-a]pirydo[3,4-e]pirymidyn- 5(1H)-on, jego sole i sposoby zastosowania
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
KR102611067B1 (ko) 2014-03-31 2023-12-06 더 스크립스 리서치 인스티튜트 Trail 유도를 위한 약리단
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
CN107427516B8 (zh) 2015-01-30 2021-04-09 昂克希尔迪克斯有限公司 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
EP3277329A4 (en) 2015-03-31 2018-12-05 The University of North Carolina at Chapel Hill Delivery vehicles for stem cells and uses thereof
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
CN108601819B (zh) 2015-12-17 2022-03-15 约翰霍普金斯大学 用死亡受体激动剂改善系统性硬化症
HRP20250207T1 (hr) 2016-01-29 2025-04-11 Oncoceutics, Inc. Modulacija g protein-spregnutog receptora (gpcr) pomoću imipridona
JP7281795B2 (ja) 2016-04-07 2023-05-26 ザ・ジョンズ・ホプキンス・ユニバーシティー 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
US10172862B2 (en) 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
WO2024030645A1 (en) 2022-08-05 2024-02-08 Chimerix, Inc. Pharmaceutical compositions and uses thereof for the treatment of glioma
WO2024102447A1 (en) * 2022-11-10 2024-05-16 Emory University Uses of hydroimidazopyridopyrimidinone derivatives for managing aneurysms or other vascular conditions or diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA105008A (en) 1907-02-06 1907-04-30 Charles B. Grimshaw Self-closing valve
DE2150062A1 (de) 1971-10-07 1973-04-12 Boehringer Sohn Ingelheim Imidazo- eckige klammer auf 1,2-a eckige klammer zu -pyrido- eckige klammer auf 4,3-d eckige klammer zu -pyrimidine, deren saeureadditionssalze und verfahren zu deren herstellung
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
WO2003055489A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
CN101336300A (zh) * 2005-12-16 2008-12-31 健泰科生物技术公司 神经胶质瘤的诊断、预后和治疗方法
AU2007213791A1 (en) 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic
US20080004286A1 (en) * 2006-06-30 2008-01-03 Schering Corporation Method of Using Substituted Piperidines that Increase P53 Activity
JP5683462B2 (ja) * 2008-07-24 2015-03-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ オーロラキナーゼ阻害剤および抗増殖剤を含む治療用組み合わせ
KR20120124353A (ko) * 2009-06-24 2012-11-13 스티븐 에반스-프레케 암 치료를 위해 코르티코트로핀 방출인자를 사용하는 방법
WO2012149546A2 (en) 2011-04-29 2012-11-01 The Penn State Research Foundation Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
HRP20191181T1 (hr) 2013-03-13 2019-10-04 Oncoceutics, Inc. 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-heksahidroimidazo[1,2-a]pirido[4,3-d]pirimidin-5(3h)-on za liječenje karcinoma

Also Published As

Publication number Publication date
MX2013012346A (es) 2014-08-22
LT3679934T (lt) 2024-11-11
ES2786033T3 (es) 2020-10-08
US20220288079A1 (en) 2022-09-15
PT2701708T (pt) 2020-05-08
US20150202206A1 (en) 2015-07-23
PT3679934T (pt) 2024-09-05
US20240415841A1 (en) 2024-12-19
DK3679934T3 (en) 2024-07-22
SI2701708T1 (sl) 2020-07-31
EP2701708A2 (en) 2014-03-05
DK2701708T3 (da) 2020-04-27
JP6132833B2 (ja) 2017-05-24
CA2832342C (en) 2019-12-31
US9061032B2 (en) 2015-06-23
ES2992934T3 (en) 2024-12-19
US8673923B2 (en) 2014-03-18
JP2014514326A (ja) 2014-06-19
RS65813B1 (sr) 2024-08-30
JP2025159099A (ja) 2025-10-17
HUE068623T2 (hu) 2025-01-28
SMT202400421T1 (it) 2024-11-15
EP2701708B1 (en) 2020-01-22
US20150265619A1 (en) 2015-09-24
US20170000790A1 (en) 2017-01-05
US9072744B1 (en) 2015-07-07
JP2019019145A (ja) 2019-02-07
EP4335511A3 (en) 2024-05-15
EP3679934B1 (en) 2024-06-05
HUE049207T2 (hu) 2020-09-28
JP2024051080A (ja) 2024-04-10
JP7600286B2 (ja) 2024-12-16
WO2012149546A2 (en) 2012-11-01
USRE46290E1 (en) 2017-01-31
PL2701708T3 (pl) 2020-11-02
MX365365B (es) 2019-05-30
SMT202000272T1 (it) 2020-07-08
EP4335511B1 (en) 2025-11-26
US9452165B2 (en) 2016-09-27
US20120276088A1 (en) 2012-11-01
CA2832342A1 (en) 2012-11-01
WO2012149546A3 (en) 2013-01-03
CY1123010T1 (el) 2021-10-29
JP2023060196A (ja) 2023-04-27
SI3679934T1 (sl) 2025-04-30
RS60186B1 (sr) 2020-06-30
HRP20200636T1 (hr) 2020-07-10
JP2016199580A (ja) 2016-12-01
EP4335511A2 (en) 2024-03-13
EP2701708A4 (en) 2015-01-07
EP3679934A1 (en) 2020-07-15
US20170224690A1 (en) 2017-08-10
PL3679934T3 (pl) 2025-01-07
HRP20241214T1 (hr) 2024-11-22
US9629842B2 (en) 2017-04-25
US20140248264A1 (en) 2014-09-04
JP2021185210A (ja) 2021-12-09
LT2701708T (lt) 2020-05-25
US12036223B2 (en) 2024-07-16
FI3679934T3 (fi) 2024-07-08
MX2019006379A (es) 2019-09-04

Similar Documents

Publication Publication Date Title
MX379539B (es) Induccion de gen de trail de molecula pequeña en celulas normales y tumorales como una terapia anticancer.
MY171561A (en) Conjugates for treating diseases caused by psma expressing cells
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
PH12013501600A1 (en) Novel heterocyclic derivatives
MX356625B (es) Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva.
TN2014000175A1 (en) Novel purine derivatives and their use in the treatment of disease
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
EA201590998A1 (ru) СВЯЗЫВАЮЩИЕСЯ С EGFR И c-Met МОЛЕКУЛЫ С ДОМЕНАМИ ФИБРОНЕКТИНА ТИПА III
MX2014016014A (es) Metodos para determinar eficacia de farmacos usando proteinas asociadas a cereblon.
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
EA201590115A8 (ru) Внеклеточная днк в качестве терапевтической мишени для бесплодия у особи женского пола и диагностического маркера
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112012016376A2 (pt) compostos de pirrolo-aminopirimida substituída
GB201209613D0 (en) New compounds
ECSP13012572A (es) Análogos de nucleótidos sustituidos
EA201790032A1 (ru) Бициклически замещённые урацилы и их применение
EA201491584A1 (ru) Способы лечения немелкоклеточного рака легких c применением комбинированного лечения с ингибитором киназы tor
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
ATE528013T1 (de) Impfstoff-zusammensetzungen
IN2014DN09228A (enExample)
MX336761B (es) Compuestos para el tratamiento de cancer.
MX340536B (es) Terapia direccionada al receptor del factor de crecimiento epidermico (egfr).
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку